On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases (65 views)
J Clin Med (ISSN: 2077-0383linking, 2077-0383electronic), 2020 Mar 15; 9(3): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.78, 5-year impact factor: 0
Url: Not available.
Keywords: Crohn’s Disease, Il-6, Adalimumab, Cytokines, Scd163, Ulcerative Colitis, Ustekinumab, Vedolizumab, Zonulin,
Affiliations:
*** IBB - CNR ***
Department of Medical Sciences, University of Turin, 1016 Turin, Italy.
Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, 10126 Turin, Italy.
Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, 10126 Turin, Italy.
References:
Not available.
J Clin Med (ISSN: 2077-0383linking, 2077-0383electronic), 2020 Mar 15; 9(3): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.78, 5-year impact factor: 0
Url: Not available.
Keywords: Crohn’s Disease, Il-6, Adalimumab, Cytokines, Scd163, Ulcerative Colitis, Ustekinumab, Vedolizumab, Zonulin,
Affiliations:
*** IBB - CNR ***
Department of Medical Sciences, University of Turin, 1016 Turin, Italy.
Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, 10126 Turin, Italy.
Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, 10126 Turin, Italy.
References:
Not available.
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (p = 0.035), and that sCD163 values were higher in patients with IBD compared to those with IBS (p = 0.042), but no association with therapy response was observed for either biomarker. Conversely, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha showed a significant reduction from baseline to week 10 of treatment, particularly in responder patients. By multivariate logistic regression analysis corrected for disease (Crohn's disease or ulcerative colitis), type of biologic drug (Infliximab, Adalimumab, Vedolizumab, or Ustekinumab) and disease activity, the reduction in IL-6 values was associated with a clinical response at 12 months of biological therapy (odds ratio (OR) = 4.75, 95% confidence interval (CI) 1.25-18.02, p = 0.022). In conclusion, the measurement of serum IL-6 in biologics-treated IBD patients may allow for the prediction of response to treatment at 12 months of therapy and thus may help with tailoring personalized treatment strategies.
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (p = 0.035), and that sCD163 values were higher in patients with IBD compared to those with IBS (p = 0.042), but no association with therapy response was observed for either biomarker. Conversely, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha showed a significant reduction from baseline to week 10 of treatment, particularly in responder patients. By multivariate logistic regression analysis corrected for disease (Crohn's disease or ulcerative colitis), type of biologic drug (Infliximab, Adalimumab, Vedolizumab, or Ustekinumab) and disease activity, the reduction in IL-6 values was associated with a clinical response at 12 months of biological therapy (odds ratio (OR) = 4.75, 95% confidence interval (CI) 1.25-18.02, p = 0.022). In conclusion, the measurement of serum IL-6 in biologics-treated IBD patients may allow for the prediction of response to treatment at 12 months of therapy and thus may help with tailoring personalized treatment strategies.
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
No results. |
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
Other filter: ([btitle,keywords] "Crohn’s Disease" O ...
Nardone OM, Ponsiglione A, De Sire R, Calabrese G, Liuzzi R, Testa A, Guarino AD, Olmo O, Rispo A, Camera L, Castiglione F
* Impact of Sarcopenia on Clinical Outcomes in a Cohort of Caucasian Active Crohn's Disease Patients Undergoing Multidetector CT-Enterography (52 views)
Nutrients (ISSN: 2072-6643linking, 2072-6643electronic), 2022 Aug 23; 14 (17 ): N/D-N/D.
Impact Factor: 4.171
View Export to BibTeX Export to EndNote
Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG
* Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis (142 views)
Medicina (ISSN: 1010-660xlinking), 2020 Jun 11; 56(6): N/D-N/D.
Impact Factor: 1.205
View Export to BibTeX Export to EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (194 views)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
View Export to BibTeX Export to EndNote
Actis GC, Pellicano R, Fagoonee S, Ribaldone DG
* History of Inflammatory Bowel Diseases (133 views)
J Clin Med (ISSN: 2077-0383linking, 2077-0383electronic), 2019 Nov 14; 8(11): N/D-N/D.
Impact Factor: 5.688
View Export to BibTeX Export to EndNote
Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M
* Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy (426 views)
Irish J Med Sci (ISSN: 0021-1265), 2017 Jul 29; 187(2): 385-392.
Impact Factor: 1.045
View Export to BibTeX Export to EndNote
Castiglione F, Mainenti PP, De Palma GD, Testa A, Bucci L, Pesce G, Camera L, Diaferia M, Rea M, Caporaso N, Salvatore M, Rispo A
* Noninvasive diagnosis of small bowel crohn's disease: Direct comparison of bowel sonography and magnetic resonance enterography (572 views)
Inflamm Bowel Dis (ISSN: 1078-0998, 1536-4844electronic, 1078-0998linking), 2013 Apr; 19(4): 991-998.
Impact Factor: 5.475
View Export to BibTeX Export to EndNote
Peluso R, Di Minno MND, Bruner V, Soscia E, Castiglione F, Manguso F, Iervolino S, Scarpa R
* Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis (438 views)
Journal Of Rheumatology (ISSN: 0315-162x), 2012 Dec; 39(12): 2332-2340.
Impact Factor: 3.258
View Export to BibTeX Export to EndNote
Selvaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The role of scintigraphic defecography in the assessment of bowel function after restorative proctocolectomy for ulcerative colitis (370 views)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 2006 Jul; 21(5): 448-452.
Impact Factor: 2.006
View Export to BibTeX Export to EndNote
Selavaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The Role Of Scientigraphic Defecography In The Assessment Of Bowel Function After Restorative Proctocolectomy For Ulcerative Colitis (298 views)
Int J Colorectal Dis, 2006; 5: 448-452.
Impact Factor: 2.017
View Export to BibTeX Export to EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (592 views)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
View Export to BibTeX Export to EndNote
* Impact of Sarcopenia on Clinical Outcomes in a Cohort of Caucasian Active Crohn's Disease Patients Undergoing Multidetector CT-Enterography (52 views)
Nutrients (ISSN: 2072-6643linking, 2072-6643electronic), 2022 Aug 23; 14 (17 ): N/D-N/D.
Impact Factor: 4.171
View Export to BibTeX Export to EndNote
Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG
* Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis (142 views)
Medicina (ISSN: 1010-660xlinking), 2020 Jun 11; 56(6): N/D-N/D.
Impact Factor: 1.205
View Export to BibTeX Export to EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (194 views)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
View Export to BibTeX Export to EndNote
Actis GC, Pellicano R, Fagoonee S, Ribaldone DG
* History of Inflammatory Bowel Diseases (133 views)
J Clin Med (ISSN: 2077-0383linking, 2077-0383electronic), 2019 Nov 14; 8(11): N/D-N/D.
Impact Factor: 5.688
View Export to BibTeX Export to EndNote
Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M
* Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy (426 views)
Irish J Med Sci (ISSN: 0021-1265), 2017 Jul 29; 187(2): 385-392.
Impact Factor: 1.045
View Export to BibTeX Export to EndNote
Castiglione F, Mainenti PP, De Palma GD, Testa A, Bucci L, Pesce G, Camera L, Diaferia M, Rea M, Caporaso N, Salvatore M, Rispo A
* Noninvasive diagnosis of small bowel crohn's disease: Direct comparison of bowel sonography and magnetic resonance enterography (572 views)
Inflamm Bowel Dis (ISSN: 1078-0998, 1536-4844electronic, 1078-0998linking), 2013 Apr; 19(4): 991-998.
Impact Factor: 5.475
View Export to BibTeX Export to EndNote
Peluso R, Di Minno MND, Bruner V, Soscia E, Castiglione F, Manguso F, Iervolino S, Scarpa R
* Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis (438 views)
Journal Of Rheumatology (ISSN: 0315-162x), 2012 Dec; 39(12): 2332-2340.
Impact Factor: 3.258
View Export to BibTeX Export to EndNote
Selvaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The role of scintigraphic defecography in the assessment of bowel function after restorative proctocolectomy for ulcerative colitis (370 views)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 2006 Jul; 21(5): 448-452.
Impact Factor: 2.006
View Export to BibTeX Export to EndNote
Selavaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The Role Of Scientigraphic Defecography In The Assessment Of Bowel Function After Restorative Proctocolectomy For Ulcerative Colitis (298 views)
Int J Colorectal Dis, 2006; 5: 448-452.
Impact Factor: 2.017
View Export to BibTeX Export to EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (592 views)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
View Export to BibTeX Export to EndNote
10 Records (10 excluding Abstracts).
Total impact factor: 33.617 (33.617 excluding Abstracts).
Total 5 year impact factor: 21.195 (21.195 excluding Abstracts).
Total impact factor: 33.617 (33.617 excluding Abstracts).
Total 5 year impact factor: 21.195 (21.195 excluding Abstracts).
65 views. Last view on Tuesday 10 September 2024, 8:27:12
ibb.cnr.it
